Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Low-density lipoproteins cause atherosclerotic cardiovascular disease
Ference, Brian A.; Ginsberg, Henry N.; Graham, Ian; Ray, Kausik K.; Packard, Chris J.; Bruckert, Eric; Hegele, Robert A.; Krauss, Ronald M.; Raal, Frederick J.; Schunkert, Heribert; Watt, Gerald F.;…
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
Effects of dalcetrapib in patients with a recent acute coronary syndrome.
In patients who had had a recent acute coronary syndrome, dalcetrapib increased HDL cholesterol levels but did not reduce the risk of recurrent cardiovascular events.
Protein carbamylation links inflammation, smoking, uremia and atherogenesis
The discovery of an alternative and quantitatively dominant mechanism for cyanate formation and protein carbamylation at sites of inflammation and atherosclerotic plaque is reported: myeloperoxidase-catalyzed oxidation of thiocyanate, an anion abundant in blood whose levels are elevated in smokers.
Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.
Pioglitazone is associated with a significantly lower risk of death, myocardial infarction, or stroke among a diverse population of patients with diabetes and is homogeneous across trials of different durations, for different comparators, and for patients with or without established vascular disease.
Antiinflammatory Properties of HDL
There are several well-documented functions of high-density lipoprotein (HDL) that may explain the ability of these lipoproteins to protect against atherosclerosis. The best recognized of these is…
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.
In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride.
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.
This study provides direct evidence for a mechanistic link between genetic determinants and activity of Pon1 with systemic oxidative stress and prospective cardiovascular risk, indicating a potential mechanism for the atheroprotective function of PON1.
Effect of torcetrapib on the progression of coronary atherosclerosis.
The CETP inhibitor torcetrapib was associated with a substantial increase in HDL cholesterol and decrease in LDL cholesterol and was also associated with an increase in blood pressure, and there was no significant decrease in the progression of coronary atherosclerosis.